KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Inventory (2016 - 2026)

Gsk has reported Inventory over the past 18 years, most recently at $8.3 billion for Q1 2026.

  • For Q1 2026, Inventory rose 9.84% year-over-year to $8.3 billion; the TTM value through Mar 2026 reached $8.3 billion, up 9.84%, while the annual FY2025 figure was $7.9 billion, 8.3% up from the prior year.
  • Inventory for Q1 2026 was $8.3 billion at Gsk, up from $7.9 billion in the prior quarter.
  • Over five years, Inventory peaked at $8.3 billion in Q1 2026 and troughed at $1.3 billion in Q1 2022.
  • A 5-year average of $6.8 billion and a median of $7.2 billion in 2024 define the central range for Inventory.
  • Biggest five-year swings in Inventory: plummeted 84.56% in 2022 and later soared 391.97% in 2023.
  • Year by year, Inventory stood at $6.0 billion in 2022, then increased by 13.05% to $6.8 billion in 2023, then grew by 6.63% to $7.3 billion in 2024, then increased by 8.3% to $7.9 billion in 2025, then increased by 5.34% to $8.3 billion in 2026.
  • Business Quant data shows Inventory for GSK at $8.3 billion in Q1 2026, $7.9 billion in Q4 2025, and $8.3 billion in Q3 2025.